In combination w/ prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT); or have received prior chemotherapy containing taxane. In combination w/ ADT & prednisone or prednisolone for the treatment of adult men w/ newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).
Patients whose underlying medical conditions might be compromised by increases in BP, hypokalemia or fluid retention eg, those w/ heart failure, recent MI or ventricular arrhythmia. History of CV disease. HTN & hypokalemia must be controlled prior to therapy. Monitor BP, serum K & fluid retention at least mthly. Monitor for adrenocortical insufficiency; symptoms of mineralocorticoid excess. Discontinue if patient develops severe hepatotoxicity. Hepatic impairment. Not for use in women.
Decreased AUC w/ CYP3A4 inducers eg, phenytoin, carbamazepine, rifampicin, rifabutin, rifapentine, phenobarb. Drugs activated or metabolized by CYP2D6 or w/ narrow therapeutic index. Drugs predominantly eliminated by CYP2C8. Decreased bone density in combination w/ a glucocorticoid.
L02BX03 - abiraterone ; Belongs to the class of other hormone antagonists and related agents. Used in the treatment of metastatic castration-resistant prostate cancer.
Manage Account
Change Password
Sign Out
